Skip to content
Credit reportVerdict and grounds
Made on 18-11-2026 at 18:09
Reference CK-1002131150-20261118

ERC Pharma

ActivePublic limited company1002.131.150Rue Jean Sonet,Isnes 10, 5032 Gembloux
Wholesale of pharmaceutical and medical goods (NACE 46460) · founded in 2023 · accounts in the micro format

Sources: the KBO register on 18-11-2026; the National Bank, 2025 annual accounts filed on 30-09-2026; the Belgian Official Gazette, latest deed of 31-03-2025.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 4,376 small companies in the wholesale trade sector (NACE 46) is 0.2%.
Gross margin
-€60,682
-€49,253 in 2024
Net result
-€179,975
-€151,962 in 2024
Equity
-€231,937
-€51,962 in 2024
Cash
-

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, ERC Pharma made a loss of €179,975.Annual accounts 2025 page 2
  2. Equity is negative: -€231,937 on 31-12-2025.Annual accounts 2025 page 2
  3. The 2025 accounts reached the National Bank on 30-09-2026, 61 days after the term.National Bank, filing of 30-09-2026 page 5
  4. (0895.963.165) holds all the shares. Its equity stood at €2.5m on 31-12-2025. That parent has 3 direct subsidiaries in 3 countries.Annual accounts 2025 of page 4

Representation

Checked did not find the signing rule in the deeds it read.

Ownership

(0895.963.165) holds all the shares. Its equity stood at €2.5m on 31-12-2025.

Annual accounts 2025 of

ERC Pharma · 1002.131.150 · credit report of 18-11-2026Page 1 of 6
ERC Pharma1002.131.150 · report of 18-11-2026

Financial situation

Annual accounts 2024 to 2025, as filed with the National Bank

Gross margin and net resultin €m

2024-0.052025-0.062024-0.22025-0.2
gross marginnet result

Equity and debtsin €m

20242025-0.23.8
equitydebts

Cashin €m

20240.002025
on the balance sheet date
Financial year202413 months2025Trend
Results
Gross margin-€49,253-€60,682
Operating result-€71,165-€79,113
Net result-€151,962-€179,975
Balance sheet at the closing date
Equity-€51,962-€231,937
Debts€3.8m€3.8m
Debts due after more than one year€2.0m€1.7m
Debts due within one year€1.7m€2.1m
Cash€36-
Balance sheet total€3.7m€3.6m
Ratios
Solvency-1.4%-6.5%
Liquidity0.260.16

Source: Annual accounts 2025, micro format, filed on 30-09-2026 (2026-00532871); Annual accounts 2024, micro format, filed on 26-08-2025 (2025-00404136).

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

ERC Pharma states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from -€49,253 to -€60,682.

The financial year to 31-12-2024 ran for 13 months.

ERC Pharma · 1002.131.150 · credit report of 18-11-2026Page 2 of 6
ERC Pharma1002.131.150 · report of 18-11-2026

Board, signature and ownership

Position on 18-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

Checked did not find the signing rule in the deeds it read.

Board

four directors in office
Chair of the board, director and managing directorappointed by deed of 13-11-2023
term until the 2029 general meetingdeed of 13-11-2023
Directorappointed by deed of 13-11-2023
deed of 13-11-2023
Directorappointed by deed of 13-11-2023
deed of 13-11-2023
Directorappointed by deed of 31-03-2025
term until the 2029 general meetingdeed of 31-03-2025

also sits on the board of 1 other company.

Ownership and group

Shareholders

(0895.963.165) holds all the shares. Its equity stood at €2.5m on 31-12-2025.

Annual accounts 2025 of

Board changes

(managing director) and resign. (managing director) and appointed. General meeting of 16-01-2025.

Gazette, deed 25042170
ERC Pharma · 1002.131.150 · credit report of 18-11-2026Page 3 of 6
ERC Pharma1002.131.150 · report of 18-11-2026

Group

has 3 direct subsidiaries in 3 countries (2025 accounts).

Country CompanyYear Equity Result
Belgium 1
BE ERC PHARMAthis company2025 -€231,937 result -€179,975
Europe 1
NL 80%2022 €99 result -
North America 1
US 80%2022 -USD 7.5m result -USD 922,683

Source: List of holdings in the 2025 accounts of . Holdings that file themselves stand with their latest accounts, the others with the amounts of that list, in their own currency.

ERC Pharma · 1002.131.150 · credit report of 18-11-2026Page 4 of 6
ERC Pharma1002.131.150 · report of 18-11-2026

Events and comparison

Every event since the founding, newest first

Annual accounts 2025 filed, 61 days late.

NBB filing

Annual accounts 2024 filed, 26 days late.

NBB filing

(managing director) and resign. (managing director) and appointed. General meeting of 16-01-2025.

Gazette, deed 25042170

First establishment. Rue Jean Sonet,Isnes 10, Gembloux.

Incorporation. Founding capital of €100,000, 100,000,000 shares. Founded by (comparant). (chair of the board), (managing director), , and appointed. Published on 13-11-2023.

Gazette, deed 23425230

In 2025, ERC Pharma had a lower net result than 95% of the 15,467 companies in the wholesale trade sector (NACE 46).

Other findings

Peppol

Reachable for e-invoices, under 0208:1002131150.

Sanctions lists

ERC Pharma · 1002.131.150 · credit report of 18-11-2026Page 5 of 6
ERC Pharma1002.131.150 · report of 18-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units18-11-2026KBO 1002.131.150
National Bank of BelgiumAnnual accounts 2025, micro format30-09-20262026-00532871
National Bank of BelgiumAnnual accounts 2024, micro format26-08-20252025-00404136
Belgian Official GazetteBoard31-03-2025deed 25042170
Peppol DirectoryRegistration for e-invoices0208:1002131150
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name16-11-2026no match
CheckedChecked score, bankruptcy probability, credit, comparable companies17-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 17-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

ERC Pharma · 1002.131.150 · credit report of 18-11-2026Page 6 of 6